Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- State governments
- County governments
- City & township governments
- For-profit businesses
- School districts
- Private colleges & universities
- Public colleges & universities
- Public & Indian housing authorities
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD. The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. These cross-ancestry, cross-disease, and cross-species approaches will enable a more comprehensive investigation of the genomic drivers of neurodegeneration and neuropathogenesis. Ultimately, this initiative may lead to the identification of actionable therapeutic targets for AD/ADRD, meeting the urgent need for mechanism-driven insights that can guide precision medicine approaches for its treatment. Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-AG-26-023
- Instrument: cooperative_agreement
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Alzheimer's
- Science research
- Seniors
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health
Amount
Up to $250,000
Deadline
October 14, 2026
Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (SMI) (R01 Clinical Trial Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 15, 2026
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $300,000
Deadline
October 16, 2026
Ready to apply for Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine. Now let's win it.